McDermott + Bull has successfully placed John Brenner as the Director of Clinical Quality Assurance at Geron Corporation. Reporting to the Vice President of Quality, John and his team will be responsible for providing GXP compliance expertise and leadership for the quality assurance group and will ensure that Geron’s products, processes, facilities, and systems conform to appropriate quality standards, governmental regulations, and GCP guidelines. He will be instrumental in integrating quality throughout all steps of the GCP process, including monitoring and auditing risk assessments and tracking and trending the key metrics to drive improved quality of the GCP activities at the company. 

John has a strong background in clinical quality assurance, with 20 plus years of experience focusing on GCP in various clinic trials. Prior to joining Geron, he was the Director of Clinical Quality Assurance at Ovid Therapeutics and the Director of GCP Quality Assurance at Axovant Sciences. His strong work ethic and expertise in this space will play an integral role in the quality department at Geron. 

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, and hematologic myeloid malignancies. Imetelstat is a novel, first-in-class telomerase inhibitor exclusively owned by Geron and is being developed in hematologic myeloid malignancies.

This executive search was completed by McDermott + Bull Partner Garrett Lipus, Managing Director Linda Sierra, Director Tim Dotson, and Executive Recruiter Quyen Doan.